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Abstract
Background: The clinical and epidemiological significance of Leishmania DNA in extralesional sites is obscured by
uncertainty of whether the DNA derives from viable parasites. To examine dissemination of Leishmania during active disease
and the potential participation of human infection in transmission, Leishmania 7SLRNA was exploited to establish viability
and estimate parasite burden in extralesional sites of dermal leishmaniasis patients.
Methods: The feasibility of discriminating parasite viability by PCR of Leishmania 7SLRNA was evaluated in relation with
luciferase activity of luc transfected intracellular amastigotes in dose-response assays of Glucantime cytotoxicity. Monocytes,
tonsil swabs, aspirates of normal skin and lesions of 28 cutaneous and 2 mucocutaneous leishmaniasis patients were
screened by kDNA amplification/Southern blot. Positive samples were analyzed by quantitative PCR of Leishmania 7SLRNA
genes and transcripts.
Results: 7SLRNA amplification coincided with luciferase activity, confirming discrimination of parasite viability. Of 22
patients presenting kDNA in extralesional samples, Leishmania 7SLRNA genes or transcripts were detected in one or more
kDNA positive samples in 100% and 73% of patients, respectively. Gene and transcript copy number amplified from
extralesional tissues were comparable to lesions. 7SLRNA transcripts were detected in 13/19 (68%) monocyte samples, 5/12
(42%) tonsil swabs, 4/11 (36%) normal skin aspirates, and 22/25 (88%) lesions; genes were quantifiable in 15/19 (79%)
monocyte samples, 12/13 (92%) tonsil swabs, 8/11 (73%) normal skin aspirates.
Conclusion: Viable parasites are present in extralesional sites, including blood monocytes, tonsils and normal skin of dermal
leishmaniasis patients. Leishmania 7SLRNA is an informative target for clinical and epidemiologic investigations of human
leishmaniasis.
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Introduction
Prevention and control of dermal leishmaniasis in the New World
continues to elude measures based on case identification and
treatment. Persistent infection [1] has favored the development of
secondary resistance and relapse following treatment and resolution
of lesions. Moreover, primary resistance [2] supports the dissemina-
tion of tolerant or resistant organisms via anthroponotic transmission.
Understanding of the dynamics and distribution of Leishmania in
the human host is fundamental to the targeting of control
measures and indeed to their evaluation. The ability to detect and
quantify live Leishmania using molecular tools would allow crucial
gaps in the natural history of human infection with Leishmania of
the Viannia subgenus to be addressed.
Diverse genetic targets and amplification methods have been
utilized for the detection, identification and quantification of
Leishmania in lesions and other tissues [3,4,5]. The persistence of
Leishmania infection following resolution of disease has been
supported by serologic, immunohistochemical and molecular
evidence. Leishmania kDNA has been the principal molecular
target, yielding evidence of parasites in extralesional tissues
including scars, normal skin, and blood monocytes [5,6,7].
However, the high stability of DNA molecules and the possibility
of its persistence following parasite death has raised questions
concerning the interpretation of its amplification from blood and
apparently healthy tissues as indicative of the presence of viable
Leishmania [8].
Because of its short half life and lability, RNA has been
considered a plausible indicator of viability and a diagnostic target
for diverse microbial infections [9]. Hence methods such as
quantitative nucleic acid sequence-based amplification (QT-
NASBA) and real time PCR have been developed and used to
www.plosntds.org 1 September 2010 | Volume 4 | Issue 9 | e819detect RNA of microbial pathogens [3,10,11]. The 18S ribosomal
gene, as well as its abundant RNA transcripts, have been used to
detect infection and to estimate parasite burden in leishmanial
lesions [10]. However, Leishmania RNA targets have yet to be
exploited to establish parasite viability or the presence of parasites
in extralesional tissues.
7SLRNA is an integral component of the signal recognition
particle, a ribonucleoprotein complex of 6 polypeptides and RNA
that mediates protein translocation across the endoplasmic
reticulum. The genetic divergence of mammalian and trypanoso-
matid 7SLRNA, its abundance in the cytoplasm [11,12], and short
half life support the feasibility of sensitive and specific detection of
live parasites by amplification of this target.
We show that 7SLRNA transcript copy number is proportional to
the number of live parasites and demonstrate the presence of
Leishmania 7SLRNA genes and transcripts in blood monocytes, normal
skin and tonsilar mucosa of patients with dermal leishmaniasis.
Materials and Methods
Ethics statement
The study protocol, informed consent and sampling procedures
were approved by the CIDEIM institutional review board for
studies involving human subjects and conducted in compliance
with national and international guidelines for the protection of
human subjects from research risks. Written informed consent was
obtained from all participants.
Parasites
Promastigotes of L. (Viannia) panamensis (MHCOM/CO/86/
1166) transfected with the firefly luciferase (LUC) (L. panamensis-
LUC) reporter gene using the pGL2-a-NEOaLUC expression
vector essentially as described [13] were cultured in Schneiders’
Drosophila medium (Sigma) [14].
Patients
Thirty patients with parasitologically confirmed active tegu-
mentary leishmaniasis were included in the study. Participants in
this study were patients consulting at Centro Internacional de
Entrenamiento e Investigaciones Medicas (CIDEIM) in Cali,
Colombia, and who were included in a prior investigation [5].
Inclusion criteria and clinical diagnosis were as previously
described [5].
Sampling
Blood monocytes, tonsil swabs, healthy skin and lesion aspirates
were obtained from patients with active parasitologically con-
firmed dermal leishmaniasis. Blood monocytes were separated
from a 10 mL sample of peripheral blood using the Nycoprep
system (1.068 g/mL; Axis Shield) following the manufacturer’s
protocol. Tonsilar swab samples were obtained by gently rubbing
with a swab developed for harvesting DNA samples (BuccalAmp
kit; Epicenter Biotechnologies). Dermal tissue fluid samples were
obtained by aspiration with a tuberculin syringe from healthy skin
sites located at a distance of 8–10 cm from cutaneous lesions in the
direction of lymphatic drainage, and from the lesion. All samples
were stored in TRIzol at -70uC until processing.
Sample processing
RNA and DNA were extracted using the AllPrep DNA/RNA
Minikit (Qiagen) in accordance with the manufacturer’s instruc-
tions. DNA was used for PCR/Southern blot and quantitative
real-time PCR (qPCR) assays. Total DNAse I-treated (Qiagen)
RNA was used for quantitative real-time reverse transcriptase
PCR (RT- qPCR).
L. Viannia kDNA was amplified from all samples by PCR using
the LVB1 primers followed by Southern blot hybridization [5].
kDNA positive samples were then evaluated by real time PCR to
detect live parasites and estimate parasite burden using 7SLRNA
transcript and gene amplification, respectively. The human
GAPDH gene was amplified as loading and inhibition control
(gene specific TaqMan assay kits, Applied Biosystems).
Real time PCR assays
Probes and primers. Real-time PCR assays were performed
to amplify a 173bp fragment of the 7SLRNA gene and its
transcript using the primers TRY7SL.For.1 and TRY7SL.Rev.1
as previously described [11]. Additionally, two specific Leishmania
7SLRNA probes that hybridized within the amplification product
were used: an ‘‘up’’ FL 39 labeled 7SL probe hybridized at the 43–
65 bp sequence of the 7SLRNA gene (59 TGC TGC GTT GAC
GTG GTG CTC TG 39), and a ‘‘down’’ LCRED 640 59labeled
7SL probe hybridized the 67–91 bp sequence (59 TTG GCT
GTG TGT CGG TGT GGC CTG C 39).
RT-qPCR and qPCR conditions. 100 ng of total RNA were
reverse transcribed using the SuperScript III first-strand synthesis
system superMix (Invitrogen). For the PCR reaction, 100 ng of
total DNA or 3 mL cDNA were added to the amplification mix
containing 4 mLo f5 6 LightCycler FastStart DNA Master
PLUS
HybProbe master mix (Roche Applied Science), 1 mM of each
primer, 0.25 mM of each FL - LCRED640 probe, and completed
to a final volume of 20 mL with ultra pure water.
Amplification and real-time measurements were performed with
a LightCycler (Roche Applied Science) under the following
conditions: 95uC for 6 min, followed by 50 PCR amplification
cycles consisting of 5 s at 95uC, 10 s at 60uC, 5 s at 72uC. In the
final cycle, the melting curve was obtained by heating at 95uC for
30 s and subsequently cooling samples at 40uC for 15 s. Each
PCR run included negative controls for PCR reagents, reverse
transcription and sample extraction. The threshold cycle value (Ct)
was calculated for each sample automatically by the LightCycler
2.0 software version 4.1 (Roche Applied Science). A standard
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Amplification of parasite gene sequences in clinical
samples from cutaneous leishmaniasis patients has pro-
vided evidence of Leishmania in blood, other tissues and
sites distinct from the lesion and of persistence of infection
after clinical resolution of disease. However, there is
uncertainty about the interpretation of the presence of
Leishmania DNA as indicative of viable parasites. Because
RNA is short-lived and labile, its presence provides an
indicator of viability. We amplified Leishmania 7SLRNA, a
molecule involved in intracellular protein translocation, to
establish viability and estimate parasite load in blood
monocytes, tonsil swab samples, and tissue fluid from
healthy skin of patients with dermal leishmaniasis. Results
showed that during active dermal leishmaniasis, viable
Leishmania are present in blood monocytes, tonsils and
normal skin in quantities similar to that in lesions,
demonstrating widespread dissemination of infection
and subclinical involvement of tissues beyond the lesion
site. Leishmania 7SLRNA will be useful in deciphering the
role of human infection in transmission.
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cloned in pCR2.1 TOPO TA vector. Ct values were plotted
against standards of known 7SLRNA plasmid concentration
ranging from 10
7 to 10
2copies/reaction, and the number of
7SLRNA copies in the samples was calculated from the standard
curve.
Cytotoxicity assay and evaluation of viability of
intracellular amastigotes
Phorbol myristate acetate (PMA)-differentiated human U937
macrophages were exposed to human AB+ serum opsonized
antimony sensitive L. panamensis-LUC promastigotes for 2 h then
washed to remove extracellular parasites. Cultures were treated
with pentavalent antimony (Sb
v) over a dose range from 2 to
32 mg/mL for 72 hr at 34uC, 5% CO2. Drug-free control was
included in all assays. Surviving intracellular L. panamensis-LUC
amastigotes were detected by luminometry, measuring luciferase
activity as an indicator of viability [15]. In parallel, identically
infected and drug-treated cells were collected and stored in TRIzol
(Invitrogen) for evaluation of parasite viability by RT-qPCR of the
7SLRNA transcripts.
Statistical analysis
Intra- and interassay variations of quantitative data for the
standard curve were measured as coefficients of variation (CV) for
each input concentration, calculated as the standard deviation/
average 6100% for each triplicate (intra-assay variation) and for
all assay output data (interassay variation). Correlation coefficients
(r
2 values) were calculated for each standard curve by linear
regression analysis. Amplification efficiency of real-time assays was
calculated as E=10
21/slope, where the slope is obtained from the
linear regression of the standard curve. Differences in copy
number between RT-qPCR and qPCR were analyzed using the
Kruskal-Wallis and Mann-Whitney non-parametric test and
significant differences were considered at p,0.05. Correlation
analyses of luminometry vs. RT-qPCR of 7SLRNA for evaluation
of parasite viability during drug dose response assays were
conducted using the Spearman coefficient.
Results
Sensitivity and specificity of the real-time PCR assay
RT-qPCR and qPCR amplification of total RNA and DNA
from serial dilutions of L. panamensis promastigotes, revealed a
lower detection limit of 10
2 parasites. As expected, the number of
copies of 7SLRNA transcripts in live culture-derived parasites was
consistently higher than the number of copies amplified from the
corresponding gene (Figure 1A). To determine the specificity of
the assay, real-time PCR was performed with RNA and DNA
extracted from L. panamensis, Trypanosoma cruzi, Mycobacterium
tuberculosis, and human blood monocytes. The Leishmania 7SLRNA
gene and RNA transcripts were amplified only from Leishmania
(Figure 1B).
The standard curve of the 7SLRNA gene cloned in pCR2.1
TOPO TA vector for the quantitative assay was linear over
concentrations of 10
2 to 10
7 copies with an r
2 of 0.998 and
efficiency of 1.977.
7SLRNA is amplified from live Leishmania
Amplification of Leishmania 7SLRNA from infected U937
macrophages was inversely related to antimony concentration
and correlated with luciferase activity (Spearman coefficient
=0.914, p=0.01) in antimony sensitive L panamensis-LUC.
7SLRNA copy number was proportional to the number of live
parasites based on light emission resulting from luciferase activity
in the dose response cytotoxicity assay (Figure 1C), confirming the
capacity to quantify live parasites using this RNA target. However
7SLRNA molecules could still be detected, although at a negligible
level, at 32 mg/ml Sb
V, a concentration at which the readout by
luminometry approached zero.
PCR of kDNA and Southern blot analysis
Leishmania kDNA was detected by PCR and/or Southern blot in
monocytes, tonsil swabs or normal skin of 22 (73%) of the 30
patients. Blood monocytes were the most frequently positive tissue:
19/28 (68%) followed by tonsil swab 13/28 (46%), and normal
skin aspirate 11/30 (37%). Lesion aspirates were positive in 26/30
(87%) of patients (Table 1).
Detection of viable parasites in extralesional sites
confirmed kDNA evidence of infection
7SLRNA gene amplification revealed the presence of Leishmania
in one or more extralesional tissues in 100% (22/22) of patients
presenting kDNA in these tissues. Amplification of RNA
transcripts confirmed the viability of parasites in one or more
extralesional samples in 16/22 (73%) of these patients. 7SLRNA
transcripts were most frequently detected in monocytes 13/19
Figure 1. Detection of live Leishmania by amplification of
7SLRNA. A: Comparison of Crossing point for DNA and RNA recovered
from ten fold dilutions of promastigotes 1610
6–1610
2 (performed in
duplicate), error bars correspond to 2 standard deviations; B: Sensitivity
and specificity of Leishmania (Viannia) panamensis 7SLRNA real time
PCR demonstrated by Amplification Plot of parasite dilutions and
negative controls indicated by asterix (PCR without cDNA, Extraction
and Retro-transcription negative controls, blood monocytes from
healthy donor, T. cruzi cDNA); C: Dose response of intracellular
Leishmania (Viannia) panamensis amastigotes transfected with pGL2-
aNEO-aLUC vector to increasing concentrations of Sb
V. Open squares,
percent reduction of 7SLRNA transcript copy number determined by
RT-qPCR, filled circles, percent reduction of light emission measured by
luminometry; D: Amplification of the 7SLRNA gene and transcripts from
different tissue samples of patients with active cutaneous leishmaniasis.
Open and filled squares correspond to median +/2 min and max RNA
and DNA copy number of 7SLRNA respectively. Significant differences
are indicated with asterisk, p=0.02. Healthy skin aspirate refers to
unaffected skin 8–10 cm distant from an active lesion.
doi:10.1371/journal.pntd.0000819.g001
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aspirates 4/11 (36%). Of 25 lesion aspirates that were positive for
kDNA, 22 (88%) contained detectable 7SLRNA transcripts
(Table 1). Human GAPDH was amplified from all samples from
which Leishmania 7SLRNA genes were not amplified.
Relative parasite burden in different sites and tissues
In contrast with the higher amplification of 7SLRNA transcripts
versus gene copies in cultured promastigotes, in tissue samples, a
higher number of copies of the 7SLRNA gene were amplified than
RNA transcripts. This difference was significant (P=0.002) for
blood monocytes and tonsil swabs (Figure 1D). Copy number
varied from 10
3 to 10
7 for both the 7SLRNA gene and transcripts.
Notably, copy number of either the 7SLRNA gene or its
transcripts did not differ significantly among the extralesional
tissues examined or compared with lesions (Figure 1D). Never-
theless, among kDNA positive extralesional samples, the 7SLRNA
gene was most frequently amplified from tonsil swabs 12/13
(92%), followed by blood monocytes 15/19 (79%) and healthy skin
aspirate 8/11 (73%). The 7SLRNA gene was amplified from of
24/26 (92%) kDNA positive lesion aspirates (Table 1).
Discussion
This study has shown 7SLRNA transcript copy number to be
correlated with the number of viable Leishmania and substantiated
the presence of live parasites in extralesional tissues of patients
with active dermal leishmaniasis. Because amplification of
7SLRNA transcripts detects the presence of live parasites, this
target allows a parasitological diagnosis to be achieved. To our
knowledge, the results of this study provide the first demonstration
of Leishmania viability in clinical samples by molecular means.
The finding of live parasite in the blood, normal skin and
mucosa of a high proportion of patients with cutaneous disease
and no clinical evidence of mucosal involvement demonstrates that
the dissemination of Leishmania to tissues without triggering disease
is common, and may characterize the natural history of human
dermal leishmaniasis attributable to species of the Viannia
subgenus. Furthermore, the high number of parasites (10
3–10
7)
in small samples of fluid and cells from apparently normal tissues
and blood as well as lesions indicate that the parasite burden in
humans with active dermal leishmaniasis is substantial. The
development of cutaneous leishmaniasis in subclinically infected
military personnel following local trauma [16] suggests that the
prevalence of parasites in normal tissues may extend to subclinical
infection.
The detection and quantification of parasites is important for
determining the status of infection, monitoring of treatment and to
resolve gaps in the understanding of the natural history of human
infection. Few attempts have been made to investigate the
presence of Leishmania in extralesional tissues of patients with
dermal leishmaniasis [5,7] and quantitative assessment of parasite
burden has focused on active lesions [3,4,10]. The frequency of
Leishmania kDNA in blood monocytes and tissue fluid from normal
skin was higher in this study than in a previous study using a
different primer combination [7]. The high analytical sensitivity of
the LV-B1 primer set [17] is confirmed by these results. In the
current study, detection of 7SLRNA gene copies and transcripts in
kDNA positive samples confirmed the specificity of kDNA
amplification from asymptomatic tissue sites, and the applicability
of this target to the detection of Leishmania in diverse tissue samples.
Since the amplified sequence from the 7SLRNA gene corresponds
to a region that has been used to distinguish Leishmania species [11]
identification of the infecting species may also be achievable.
Leishmania ribosomal RNA genes (10
2) and transcripts (10
4) are
more abundant than 7SLRNA genes (10
1) or transcripts (10
2) and
could provide a more sensitive target [11,12,18]. However the
relationship between ribosomal RNA gene transcript copy number
and parasite viability has not been established and the high and
potentially variable number of gene copies in different species and
strains [18], while advantageous for detection, could confound
estimation of parasite burden.
In this study the efficiency of recovery of Leishmania 7SLRNA
transcripts from patient samples was lower than that of the
corresponding genomic sequences despite the higher copy number
of transcripts observed in cultured promastigotes. The lower
recovery from patient samples is consistent with the shorter half
life, lability and vulnerability of RNA to degradation in vivo, as well
as during sample processing [9,19]. Nevertheless, 7SLRNA
transcripts were detected in the majority (64%) of kDNA positive
samples. The association of 7SLRNA with six polypeptides in the
signal recognition particle may confer stability and favor recovery
of this parasite RNA molecule [20].
Because of the persistence of DNA after cell death, RNA targets
have been exploited for the assessment of the viability of microbial
pathogens [9]. However, the size and the location of the target
sequence within a gene transcript can influence the efficiency of
detection and correlation of its presence with viability [21].
Although shorter sequences are more sensitive targets for PCR
reactions they are also more likely to persist intact in non-viable
cells whereas longer sequences are more vulnerable to degradation
and hence have been more closely correlated with viability defined
by replication in culture [19].
The real time PCR assay used in this study was based on a short
hypervariable internal sequence (178 bp) of the 7SLRNA gene
flanked by conserved primer binding sites. The relatively short
length of the amplified target might have contributed to the
residual presence at high drug concentration in vitro. Nevertheless,
the correlation of copy number of 7SLRNA transcripts with the
dose and time dependent reduction of parasite viability in response
to Glucantime substantiates the validity of this target as a marker
of viability.
Although Leishmania have occasionally been isolated from blood
or aspirates from normal skin of patients with dermal leishmaniasis
[1,7,22,23], conventional parasitological methods are inefficient
and of low sensitivity. Real time amplification of the 7SLRNA
gene or transcripts provides a rapid and efficient method for the
Table 1. Frequency of detection of parasite kDNA, and
7SLRNA genes and transcripts in blood monocytes, healthy
skin aspirate, tonsil swab and lesion aspirates from patients
with active cutaneous leishmaniasis.




Blood 19/28 (68) 15/19 (79) 13/19 (68)
Tonsil Swab 13/28 (46)
a 12/13 (92) 5/12
b (42)
Healthy Skin Aspirate
c 11/30 (37) 8/11 (73) 4/11 (36)
Lesion Aspirate 26/30 (87) 24/26 (92) 22/25 (88)
b
aData from Figueroa et al, 2009.
bRNA was not detected in one sample.
cUnaffected skin site 8–10 cm distant from active lesion.
doi:10.1371/journal.pntd.0000819.t001
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Isothermal sequence amplification (QT-NASBA) of 18SRNA has
been successfully used to detect and quantify Leishmania in lesion
biopsies obtained from patients with cutaneous leishmaniasis
before and after treatment with a lower limit of detection of 2
parasites [10]. Based on the assumption that approximately 250
7SLRNA transcripts are present per cell [12], the limit of detection
of RT-qPCR of 7SLRNA, according to the plasmid-derived
standard curve, was 10 parasites in lesion aspirates and 5 parasites
in blood monocytes. Despite its higher sensitivity compared to
Real Time PCR, QT-NASBA is a more complex and demanding
method [24].
In conclusion, Leishmania viability, parasite burden and infection
of extralesional tissues can be parasitologically established by
amplification of 7SLRNA genes and transcripts. During active
dermal leishmaniasis, viable Leishmania are present in blood
monocytes, tonsils and normal skin, demonstrating dissemination
of infection without triggering pathogenesis. 7SLRNA genes and
transcripts are informative targets for clinical and epidemiologic
studies to elucidate the natural history of human leishmaniasis and
the participation of human infection in transmission, and may also
be useful in the evaluation of immunoprophylaxis and other
preventive intervention strategies.
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